{ "schemaVersion": "deck-intelligence.v1", "id": "019de074-1527-7308-955d-4c9eab2bbacb", "slug": "e812f3c221148b99b15c4527dea8f94b", "title": "argenx SE | Results Presentation Deck | 15 slides", "subtitle": "argenx · 2022-12", "author": "argenx", "date": "2022-12-01 00:00:00", "pageCount": 15, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de074-1527-7308-955d-4c9eab2bbacb", "slug": "e812f3c221148b99b15c4527dea8f94b", "title": "argenx SE | Results Presentation Deck | 15 slides", "rawTitle": "argenx SE | Results Presentation Deck | 15 slides", "authorId": "argenx-se", "authorName": "argenx", "authorDisplay": "argenx", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2022-12__argenx-se__results__e812f3c2.pdf", "sourceUrl": "https://www.slidebook.io/company/argenx-se/presentation/e812f3c221148b99b15c4527dea8f94b/", "sourceDate": "2022-12-10 00:00:00", "presentationDate": "2022-12-01 00:00:00", "ingestedAt": "2026-04-30 22:13:17.324964+00", "status": "ready", "pageCount": 15, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2022-12__argenx-se__results__e812f3c2", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Results Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 15, "pagesIndexed": 15, "pagesWithImages": 15, "pagesWithMetadata": 15, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 56, "chartCount": 5, "metricSlides": 0, "toolMatches": 5, "documentToolMatches": 0, "frameworkMatches": 5, "arcMatches": 1, "beatMatches": 6, "loopMatches": 1, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "evidence": "The presentation follows a logical sequence from problem statement to solution demonstration.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:28:48.230501+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 2, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 2, "name": "Problem Identification", "beatId": "6bac841b-f3a0-487f-b726-eae836669891", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The document starts with a problem statement (slide 2).", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Agitation", "beatId": "44cfae2d-c3bc-4381-9103-a4632e118ac7", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Baseline characteristics show multiple prior therapies and long-standing ITP (slide 6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "09955424-6993-4704-aa8b-9fa2132842c0", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Efficacy endpoints were met (slide 7).", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 8, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Before-After Comparison", "beatId": "6f29d594-528b-4f58-985e-68a47d3c3290", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod demonstrated early sustained increases in platelet counts (slide 8).", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Comparative Analysis", "beatId": "0c059d1b-2ec8-469b-85a9-f147e99468f3", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod resulted in higher responses than placebo (slide 9).", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 14, "name": "Key Takeaways", "beatId": "3200b2c0-e740-44b5-8fc8-5bd350f76fb3", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions (slide 14).", "position": 5, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 11, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "23e75dc1-17d4-4126-ac6f-02b66dffe107", "evidence": "Sustained Platelet Count Response by Subgroup Analysis.", "position": 0, "objective": "Show subgroup analysis favoring efgartigimod", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:48.517853+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Visual Anchors", "slug": "visual-anchors", "status": "active", "bestFor": null, "canonId": "019dd956-c264-7357-a791-89fa5f02a400", "version": 1, "bodyDocId": null, "description": "Design elements that guide users' eyes through the content intentionally", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5ed51740-3538-42f8-a771-78e526d8adfc", "evidence": "Biological diagram of endosomal pathway", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:18.612891+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "41e23019-4a31-41f9-8b84-437e0bf6cf9e", "evidence": "Primary and secondary efficacy endpoints comparing Efgartigimod vs Placebo with p-values", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:16:18.830442+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "89b97d04-d5a6-4782-9279-64351f1b08dd", "evidence": "Line chart showing platelet count change over 24 weeks", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:18.916073+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0be09c2-d63a-4c29-9e30-2eb268c3081f", "evidence": "chart/bar-horizontal: Extent of Disease Control (≥50×10⁹/L): Cumulative Number of Weeks of Disease Control", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:19.047891+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "23670c95-3fd9-4b30-8246-67e7ab39ce93", "evidence": "Mean IgG levels decreased steadily over the first 4 weeks of treatment, which was sustained across time and corresponded with platelet count responses", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:19.177483+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d3289ef5-f960-4954-bd8a-8c8f02c29f1a", "evidence": "The slide links the disease mechanism (autoantibodies) to specific physiological outcomes (clearance, production, function).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "causal-chain" }, { "matchId": "4da6a5d4-c1be-4231-90ff-912f7760db2d", "evidence": "The slide uses a timeline-based visual to represent the clinical trial phases and dosing schedule.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "gantt-chart" }, { "matchId": "dd36e287-ddbf-4c71-af6f-99e917388d47", "evidence": "Standard clinical trial participant disposition flow chart", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:16:24.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "CONSORT flow diagram" }, { "matchId": "684af4e2-2c75-4345-bc8a-f192b93bf791", "evidence": "Compares treatment group against placebo group to show improvement.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" }, { "matchId": "4d72010a-5cd4-417b-a597-df533292c9b0", "evidence": "Standard statistical visualization for subgroup analysis with confidence intervals", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:16:23.887+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "forest-plot" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/7qA6R1JCWWrLK9VPJZfDQZZSCoeD7vTp6pvbiuvWxjQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lODEyZjNjMjIxMTQ4Yjk5YjE1YzQ1MjdkZWE4Zjk0Yi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 4, "textChars": 1404, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:21.319+00", "seconds": 3.174, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/1", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-1", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.65 }, "kind": "paragraph", "text": "Catherine M. Broome,1 Vickie McDonald,2 Yoshitaka Miyakawa,3 Monica Carpenedo,4 David J. Kuter,5 Hanny Al-Samkari,5 James B. Bussel,6 Marie Godar,7 Jaume Ayguasanosa,7 Kristof De Beuf,7 Francesco Rodeghiero,8 Marc Michel,9 Adrian Newland,10 in collaboration with the ADVANCE IV Study Group", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1cb72dac-5fef-42ac-90f6-3e9e3f292781", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.78 }, "kind": "source-note", "text": "1Georgetown University, Washington DC, USA; 2Barts Health NHS Trust, London, UK; 3Saitama Medical University Hospital, Saitama, Japan; 4ASST Ospedale San Gerardo di Monza, Hematology and Transplant Unit, Monza, Italy; 5Massachusetts General Hospital, Boston, MA, USA; 6Weill Cornell Medical College, New York, NY, USA; 7argenx, Ghent, Belgium; 8Haematology Project Foundation, Affiliated with the Department of Haematology, S. Bortolo Hospital, Vicenza, Italy; 9Department of Internal Medicine, National Reference Center for Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France; 10Centre for Haematology, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, UK", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11170ccd-e207-4859-92dd-ad7bd988d51d", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.07, "y": 0.92 }, "kind": "source-note", "text": "Presented at the 64th Annual American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA, USA.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30b6ac56-932f-420d-a8dd-554a780cae18", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.85, "x": 0.07, "y": 0.33 }, "kind": "title", "text": "Efficacy and Safety of Intravenous Efgartigimod in Adults With Primary Immune Thrombocytopenia: Results of ADVANCE IV, a Phase 3, Multicenter, Double-blinded, Placebo-controlled, Randomized Clinical Trial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6fc428b-2ed2-4820-acb6-139f8f0f4488", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/naKBqZ21VxTZEn2lLbKRRpfCIRhLAFWR3mAZLW9tTR0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lODEyZjNjMjIxMTQ4Yjk5YjE1YzQ1MjdkZWE4Zjk0Yi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/MwEAmHGcRbx2aMidSneX0ic7svw3nVKbYgrAWWkJC0M/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lODEyZjNjMjIxMTQ4Yjk5YjE1YzQ1MjdkZWE4Zjk0Yi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/wN-w4tQB9e47hGDo3F1uNjMwJDZybsjdpmOaEzoNong/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9lODEyZjNjMjIxMTQ4Yjk5YjE1YzQ1MjdkZWE4Zjk0Yi9wMDAxLnBuZw" }, { "page": 2, "type": "tension", "title": "Includes a hub-and-spoke diagram illustrating the effects of pathogenic autoantibodies.", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 531, "nDataPoints": 0, "notes": "Includes a hub-and-spoke diagram illustrating the effects of pathogenic autoantibodies.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:25.328+00", "seconds": 7.064, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/2", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-2", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.35, "x": 0.63, "y": 0.0025 }, "kind": "diagram", "text": "Pathogenic autoantibodies lead to increased platelet clearance, inhibited platelet production, and impacted platelet function.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd6ccc18-aa82-42b1-b0d9-e40fa109e273", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.55, "x": 0.1, "y": 0.2 }, "kind": "paragraph", "text": "ITP is an acquired autoimmune disorder characterized by a reduction in platelet count, which can result in: Increased risk of bleeding, Fatigue, Decreased quality of life. IgG autoantibodies target glycoproteins. Current treatments have limitations. Need for better therapy.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35e4d57b-d948-4713-8023-9dba32ea4bf1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.1, "y": 0.88 }, "kind": "source-note", "text": "IgG = immunoglobulin G; ITP = immune thrombocytopenia; QoL = quality of life. References 1-11.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40dab8f9-7e91-497b-9749-108777f1f838", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.09, "y": 0.07 }, "kind": "title", "text": "Primary Immune Thrombocytopenia (ITP)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0af54332-dfa5-47ad-8123-a50bf6a03082", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d3289ef5-f960-4954-bd8a-8c8f02c29f1a", "evidence": "The slide links the disease mechanism (autoantibodies) to specific physiological outcomes (clearance, production, function).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:16:25.328+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "frameworkName": "causal-chain" } ], "arcBeats": [ { "to": 2, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 2, "name": "Problem Identification", "beatId": "6bac841b-f3a0-487f-b726-eae836669891", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Problem (Identify pain)", "slug": "problem-agitate-solution-problem-identify-pain", "status": "active", "canonId": "019dd9b8-0e78-74bb-b8f6-54348367a131", "version": 1, "description": null }, "evidence": "The document starts with a problem statement (slide 2).", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 3, "type": "appendix", "title": "The slide uses a visual process flow to explain the competitive inhibition mechanism.", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 4, "textChars": 241, "nDataPoints": 0, "notes": "The slide uses a visual process flow to explain the competitive inhibition mechanism.", "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:21.396+00", "seconds": 2.894, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/3", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-3", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.45, "x": 0.25, "y": 0.18 }, "kind": "image", "text": "Biological diagram of endosomal pathway", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2736bcc3-5595-4f8a-8563-ead17144f5bc", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.15, "x": 0.7, "y": 0.28 }, "kind": "list", "text": "IgG autoantibody, IgG antibody, FcRn, Efgartigimod alfa", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9930279f-ac53-47a4-a459-68f8234d865d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.1, "y": 0.92 }, "kind": "source-note", "text": "FcRn = neonatal Fc receptor; IgG = immunoglobulin G. 1. VYVGART. Prescribing information. argenx; 2021. ...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa4857c7-21ee-45d3-90ac-2884745eaeb9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.09, "y": 0.07 }, "kind": "title", "text": "Efgartigimod Competitively Inhibits FcRn", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c719e30-0bb6-47a0-b4d4-52e886de0225", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Visual Anchors", "slug": "visual-anchors", "status": "active", "bestFor": null, "canonId": "019dd956-c264-7357-a791-89fa5f02a400", "version": 1, "bodyDocId": null, "description": "Design elements that guide users' eyes through the content intentionally", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5ed51740-3538-42f8-a771-78e526d8adfc", "evidence": "Biological diagram of endosomal pathway", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:18.612891+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "appendix", "title": "The slide uses a timeline-based process flow to illustrate the clinical trial protocol.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 552, "nDataPoints": 4, "notes": "The slide uses a timeline-based process flow to illustrate the clinical trial protocol.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:26.898+00", "seconds": 8.239, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/4", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-4", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.85, "x": 0.1, "y": 0.25 }, "kind": "diagram", "text": "Study design timeline showing screening, randomization, treatment period (24 weeks), and follow-up/extension.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "57bc7b4a-81ab-4091-876a-2c82a2c80e7f", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.65, "x": 0.25, "y": 0.7 }, "kind": "list", "text": "Eligibility criteria: Age >=18, Chronic/persistent ITP, platelet counts <30x10^9/L, prior treatments, concurrent therapy permitted.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "448a91bb-c361-4dc6-a19a-55a8d55f692b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.8, "x": 0.09, "y": 0.92 }, "kind": "source-note", "text": "q2w if >=100x10^9/L for 3 of 4 visits... Concurrent oral corticosteroids, oral immunosuppressants, dapsone, danazol, fostamatinib, and oral thrombopoietin receptor agonists (not romiplostim).", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "39211466-ee13-49b3-ab87-4205bfc86f62", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.09, "y": 0.18 }, "kind": "subtitle", "text": "Phase 3, Multicenter, Double-blinded, Placebo-controlled, Randomized Clinical Trial", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7272f518-c8a0-473c-beb4-c466ee45e775", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.09, "y": 0.07 }, "kind": "title", "text": "ADVANCE IV (NCT04188379): Study Design", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a807f86-0f8a-4ac3-ba18-3b9762a27193", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4da6a5d4-c1be-4231-90ff-912f7760db2d", "evidence": "The slide uses a timeline-based visual to represent the clinical trial phases and dosing schedule.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:16:26.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "evidence", "title": "Standard clinical trial participant flow diagram.", "function": "illustrate_case", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "sparse", "densityScore": 16, "componentCount": 2, "textChars": 81, "nDataPoints": 28, "notes": "Standard clinical trial participant flow diagram.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:24.571+00", "seconds": 5.752, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/5", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-5", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.66, "x": 0.17, "y": 0.17 }, "kind": "diagram", "text": "CONSORT flow diagram", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2faea270-9243-4f16-baab-92dbec6c76be", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.82, "x": 0.09, "y": 0.07 }, "kind": "title", "text": "Participants Were Randomized 2:1 and Most Completed Treatment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3605303c-bd8b-4072-be95-3e8b67e9d0b2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "dd36e287-ddbf-4c71-af6f-99e917388d47", "evidence": "Standard clinical trial participant disposition flow chart", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:16:24.571+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "CONSORT flow diagram" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "analysis", "title": "Red boxes highlight key clinical history metrics: time since diagnosis, splenectomy history, prior therapies, and concurrent therapy usage.", "function": "analyze_data", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 3, "textChars": 434, "nDataPoints": 48, "notes": "Red boxes highlight key clinical history metrics: time since diagnosis, splenectomy history, prior therapies, and concurrent therapy usage.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:26.153+00", "seconds": 6.896, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/6", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-6", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.65, "x": 0.08, "y": 0.92 }, "kind": "disclaimer", "text": "Safety Analysis Set. ITP = immune thrombocytopenia; SD = standard deviation; TPO-RA = thrombopoietin receptor agonists; WHO = World Health Organization.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "260bc09f-97c0-438a-8ef5-a997c4ddebca", "parentComponentId": null }, { "bbox": { "h": 0.72, "w": 0.85, "x": 0.08, "y": 0.18 }, "kind": "table", "text": "Baseline characteristics table comparing Efgartigimod (n=86) and Placebo (n=45) across age, gender, diagnosis time, splenectomy, WHO bleeding score, and prior therapies.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06f2c99a-1c51-4a9b-8f6a-8b214f92939b", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.08, "y": 0.05 }, "kind": "title", "text": "Baseline Characteristics Indicate the Majority of Participants Had Multiple Prior Therapies and Long-standing ITP", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:26.153+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc727aea-9864-4ba7-8ca5-e29d34c6e605", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 6, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 6, "name": "Agitation", "beatId": "44cfae2d-c3bc-4381-9103-a4632e118ac7", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Agitate (Make it worse)", "slug": "problem-agitate-solution-agitate-make-it-worse", "status": "active", "canonId": "019dd9b8-0f5a-71dd-bae7-8fadb0d09456", "version": 1, "description": null }, "evidence": "Baseline characteristics show multiple prior therapies and long-standing ITP (slide 6).", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Development", "slug": "development", "status": "active", "canonId": "019dd9b8-0332-7008-b3aa-11b0840a57b1", "version": 1, "description": "The middle stretch in arcs that have one. Often where length problems creep in." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "analysis", "title": "The slide uses a hierarchical testing procedure for statistical significance.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 3, "textChars": 450, "nDataPoints": 24, "notes": "The slide uses a hierarchical testing procedure for statistical significance.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:21.494+00", "seconds": 2.179, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/7", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-7", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.75, "x": 0.09, "y": 0.865 }, "kind": "disclaimer", "text": "All endpoints were statistically tested in a fixed sequence to maintain an overall statistical significance level or alpha value of 5%. Although endpoints were subjected to a hierarchical testing procedure, nominal p-values are always less than 0.05 for platelet-based endpoints.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5f18dfd-32be-4cb4-8aad-b79935ff4c89", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.85, "x": 0.09, "y": 0.195 }, "kind": "table", "text": "Primary and secondary efficacy endpoints comparing Efgartigimod vs Placebo with p-values.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1276849b-92ca-4bb7-8ced-5abfe1778ea1", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.09, "y": 0.03 }, "kind": "title", "text": "Efficacy Endpoints: Primary and All Platelet-related Secondary Endpoints Were Met*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72847605-2f66-406e-9771-298a3c51e475", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "41e23019-4a31-41f9-8b84-437e0bf6cf9e", "evidence": "Primary and secondary efficacy endpoints comparing Efgartigimod vs Placebo with p-values", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:16:18.830442+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "09955424-6993-4704-aa8b-9fa2132842c0", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": { "name": "Solution (Provide relief)", "slug": "problem-agitate-solution-solution-provide-relief", "status": "active", "canonId": "019dd9b8-0fee-73e9-9ae5-799c7f3895cd", "version": 1, "description": null }, "evidence": "Efficacy endpoints were met (slide 7).", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "evidence", "title": "The chart includes error bars and a table of participant counts at the bottom.", "function": "analyze_data", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 436, "nDataPoints": 12, "notes": "The chart includes error bars and a table of participant counts at the bottom.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:21.867+00", "seconds": 2.528, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/8", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-8", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.55, "x": 0.12, "y": 0.25 }, "kind": "chart", "text": "Line chart showing platelet count change over 24 weeks", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1effccd7-646d-4b2b-a255-1980d12ff9df", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.7, "y": 0.4 }, "kind": "list", "text": "33 (38.4%) of efgartigimod treated participants compared to 5 (11.1%) placebo reached a platelet count of 30X10^9 platelets at week 1. Sustained platelet count response achieved in 90% (9/10) of participants who switched from weekly to every other week dosing.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc6b630a-19d9-42a2-9288-7e04e49f3b91", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.1, "y": 0.94 }, "kind": "source-note", "text": "*Analyzed on Full Analysis Set. LS = least squares.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "204373e2-2a49-4e9f-a8cb-9f895633bff7", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.09, "y": 0.05 }, "kind": "title", "text": "Efgartigimod Demonstrated Early Sustained Increases in Platelet Counts*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:21.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6cea56b-2311-4081-b14b-a2ba2c09243a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "89b97d04-d5a6-4782-9279-64351f1b08dd", "evidence": "Line chart showing platelet count change over 24 weeks", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:18.916073+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 8, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 8, "name": "Before-After Comparison", "beatId": "6f29d594-528b-4f58-985e-68a47d3c3290", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod demonstrated early sustained increases in platelet counts (slide 8).", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "analysis", "title": "The slide uses a stacked bar chart to visualize the response rates and a table to detail specific IWG criteria outcomes.", "function": "analyze_data", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 5, "textChars": 774, "nDataPoints": 18, "notes": "The slide uses a stacked bar chart to visualize the response rates and a table to detail specific IWG criteria outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:29.532+00", "seconds": 9.687, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/9", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-9", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.6, "x": 0.09, "y": 0.7 }, "kind": "callout", "text": "Based on analysis of IWG response criteria, which incorporate the absence of bleeding events, results were clinically meaningful", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:29.532+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54f258fc-b39e-40a6-b477-52b707ffc4e6", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.25 }, "kind": "chart", "text": "Percentage of IWG Responders", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:29.532+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9eaecd57-36f2-4d2d-aeac-366282f2ec78", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.09, "y": 0.85 }, "kind": "source-note", "text": "Pre-defined analyses, Full Analysis Set. Platelet counts of at least 100x10^9/L and the absence of bleeding events (WHO Grading = 0) for at least 2 separate, consecutive analysis visits which were at least 7 days apart.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:29.532+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7a664fe-430a-4c3e-b0b6-badbf58eac24", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.6, "x": 0.09, "y": 0.33 }, "kind": "table", "text": "Criterion, Efgartigimod (n=86), Placebo (n=45), Difference in response (95% CI); IWG complete response, 24 (27.9), 2 (4.4), 23.5 (10.3; 35.0); IWG response, 44 (51.2), 9 (20.0), 31.2 (13.8; 46.0); IWG initial response, 27 (31.4), 3 (6.7), 24.7 (10.3; 37.0)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:29.532+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dea2ef0d-3e9b-4b54-8497-808aa0c4fc55", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.08, "y": 0.05 }, "kind": "title", "text": "Efgartigimod Resulted in Higher Responses than Placebo on Analysis of IWG Response Criteria, Consistent with Previous Platelet Response Results", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:29.532+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc96e8d2-1ffb-46d9-a815-fcac185750f4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 9, "name": "Comparative Analysis", "beatId": "0c059d1b-2ec8-469b-85a9-f147e99468f3", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod resulted in higher responses than placebo (slide 9).", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "evidence", "title": "The chart uses a back-to-back bar structure to visualize the distribution of disease control duration.", "function": "analyze_data", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 246, "nDataPoints": 16, "notes": "The chart uses a back-to-back bar structure to visualize the distribution of disease control duration.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:22.9+00", "seconds": 2.979, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/10", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-10", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.75, "x": 0.15, "y": 0.2 }, "kind": "chart", "text": "Extent of Disease Control (≥50×10⁹/L): Cumulative Number of Weeks of Disease Control", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ff90f01-7730-479e-b945-fa61181b1e8e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.1, "y": 0.96 }, "kind": "disclaimer", "text": "*Analyzed on Full Analysis Set - Chronic", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "549df35b-6314-4cd1-a0d1-f9f2ae9c35b2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.45, "y": 0.9 }, "kind": "legend", "text": "EFGARTIGIMOD n=78 PLACEBO n=40", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b3c1e0d-2892-4b7e-9547-b0bbc21d2e60", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.82, "x": 0.09, "y": 0.03 }, "kind": "title", "text": "Efgartigimod-treated Participants Experienced Substantially More Weeks With Disease Control*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56d986d2-abfc-4424-ba42-3b75d60fa6ad", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0be09c2-d63a-4c29-9e30-2eb268c3081f", "evidence": "chart/bar-horizontal: Extent of Disease Control (≥50×10⁹/L): Cumulative Number of Weeks of Disease Control", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:19.047891+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "684af4e2-2c75-4345-bc8a-f192b93bf791", "evidence": "Compares treatment group against placebo group to show improvement.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:16:22.9+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 11, "type": "analysis", "title": "The chart displays point estimates and 95% confidence intervals for the treatment effect across multiple clinical and demographic categories.", "function": "analyze_data", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 3, "textChars": 308, "nDataPoints": 40, "notes": "The chart displays point estimates and 95% confidence intervals for the treatment effect across multiple clinical and demographic categories.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:23.887+00", "seconds": 3.451, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/11", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-11", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.7, "x": 0.15, "y": 0.15 }, "kind": "chart", "text": "Forest plot of subgroup analysis", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.887+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "179c5365-bc79-43a9-9452-8d393073c5a8", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.1, "y": 0.95 }, "kind": "disclaimer", "text": "*Full Analysis Set. CI = confidence interval; EEA = European Economic Area; EFTA = European Economic Area; EU = European Union; ITP = immune thrombocytopenia; TPO-RA= thrombopoietin receptor agonists.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.887+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd0fb2eb-cef6-4c58-9e20-4e7672fd66db", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.09, "y": 0.02 }, "kind": "title", "text": "Sustained Platelet Count Response by Subgroup Analysis Favored Efgartigimod*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.887+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70063b1e-770d-466e-8758-88f86274dd3d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4d72010a-5cd4-417b-a597-df533292c9b0", "evidence": "Standard statistical visualization for subgroup analysis with confidence intervals", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:16:23.887+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "forest-plot" } ], "arcBeats": [], "loops": [ { "to": 11, "from": 11, "loop": { "name": "40_mece_breakdown", "slug": "40-mece-breakdown", "status": "active", "bestFor": "Problem structuring, ensuring completeness, strategic analysis", "canonId": "019dd956-763c-765e-8b68-6ee3ae1ef184", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage", "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories", "familyLabel": null }, "matchId": "23e75dc1-17d4-4126-ac6f-02b66dffe107", "evidence": "Sustained Platelet Count Response by Subgroup Analysis.", "position": 0, "objective": "Show subgroup analysis favoring efgartigimod", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:28:48.517853+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "evidence", "title": "The chart displays a significant, sustained reduction in IgG levels for the treatment group compared to placebo.", "function": "analyze_data", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 4, "textChars": 508, "nDataPoints": 50, "notes": "The chart displays a significant, sustained reduction in IgG levels for the treatment group compared to placebo.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:23.706+00", "seconds": 3.19, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/12", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-12", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.7, "x": 0.15, "y": 0.23 }, "kind": "chart", "text": "Mean % Change from Baseline in Total IgG Levels over Time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ece1fc32-c110-4f38-b6de-5ffef196291e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.72, "x": 0.14, "y": 0.75 }, "kind": "paragraph", "text": "Mean IgG levels decreased steadily over the first 4 weeks of treatment, which was sustained across time and corresponded with platelet count responses. After the initial decrease in IgG, mean maximum reductions from baseline remained >60% throughout the trial", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "19b43b8e-4bec-4d26-96ab-f96b810bb45d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.1, "y": 0.94 }, "kind": "source-note", "text": "*Full Analysis Set. †Errors bars are standard errors around the least squares (LS) means. IgG = immunoglobulin G; SE = standard error.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3eeb6433-26e7-4b4b-94f8-16038b06286c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.09, "y": 0.08 }, "kind": "title", "text": "Efgartigimod Resulted in Targeted Reduction of IgG Levels*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1475bbd-4cd4-48be-bbbb-ae90f5b6bb0d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Before/after framing", "slug": "before-after-framing", "status": "active", "bestFor": "For turnaround / reform proposals", "canonId": "019dd9e1-528b-72ec-a563-e5dcb9410f67", "version": 1, "bodyDocId": "019dd9a1-80bf-72e9-980b-ccd1c0cd3488", "description": "You visualise two futures side by side: the trajectory the target is on\ntoday, and the trajectory under your proposed intervention. The reader\nhas to see the delta to feel the stakes.\n\nIt's the rhetorical cousin of the peer-gap — same visual grammar\n(comparison), but across **time** instead of across peers.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "23670c95-3fd9-4b30-8246-67e7ab39ce93", "evidence": "Mean IgG levels decreased steadily over the first 4 weeks of treatment, which was sustained across time and corresponded with platelet count responses", "pageRefs": null, "priority": null, "whenToUse": "For turnaround / reform proposals", "confidence": 0.7, "extraction": { "at": "2026-07-17 00:16:19.177483+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": "- It **quantifies the opportunity cost** of inaction. \"Doing nothing\"\n becomes a concrete, visible path, not an abstraction.\n- It **makes the Answer tangible**. The prescription isn't a paragraph;\n it's a trajectory the reader can point at.\n- It **pre-empts the status-quo defence**. Management usually argues \"we\n have a plan\". Your chart shows what their plan looks like vs. yours.\n- It **satisfies both the Architect** (math adds up) **and the Storyteller**\n (emotional delta between two futures).", "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 13, "type": "analysis", "title": "The table compares adverse events (TEAEs) and specific common events between treatment and placebo groups.", "function": "analyze_data", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 3, "textChars": 359, "nDataPoints": 30, "notes": "The table compares adverse events (TEAEs) and specific common events between treatment and placebo groups.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:24.2+00", "seconds": 2.661, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/13", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-13", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.11, "y": 0.93 }, "kind": "disclaimer", "text": "AESI = adverse event of special interest (defined per protocol); ITP = immune thrombocytopenia; PI = principal investigator; TEAE = treatment-emergent adverse event.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.2+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7dc25912-9380-4b3b-b20b-2823bcdb6c85", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.78, "x": 0.11, "y": 0.2 }, "kind": "table", "text": "Comparison of TEAEs and common adverse events between Efgartigimod (n=86) and Placebo (n=45)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.2+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc996d14-7bc6-4501-ad69-927a6c883fce", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.09, "y": 0.05 }, "kind": "title", "text": "Efgartigimod Was Well-Tolerated in Patients With ITP and Consistent With Other Efgartigimod Studies1-5", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.2+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a079dd55-42f2-486e-9d07-57d2e3891f9a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "resolution", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 6, "textChars": 642, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:24.257+00", "seconds": 2.567, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/14", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-14", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.85, "x": 0.113, "y": 0.225 }, "kind": "list", "text": "The benefits of targeting FcRn and lowering total IgG levels were demonstrated by clinically and statistically significant improvements in platelet counts compared with placebo", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "059af3cf-7156-4800-8581-b5bffc667102", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.113, "y": 0.615 }, "kind": "list", "text": "The results of the study support both weekly and every-other-week administration, allowing for adjustments based on platelet counts", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "063fba4d-920c-42d7-a2cb-a602fa29932d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.113, "y": 0.78 }, "kind": "list", "text": "Over 90% of participants who completed ADVANCE IV enrolled in the open-label extension (ADVANCE+; NCT04225156)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f1bce4c-c4f5-40ce-b3de-2f3a7635fc61", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.113, "y": 0.45 }, "kind": "list", "text": "Efgartigimod was well-tolerated and most adverse events were mild to moderate with no new safety signals", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "710c505c-44a4-421f-af38-9a9ad70a4b40", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.101, "y": 0.96 }, "kind": "source-note", "text": "FcRn = neonatal Fc receptor; IgG = immunoglobulin G; IV = intravenous.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "098987ed-5d51-4613-a473-27b82c73bb34", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.55, "x": 0.098, "y": 0.085 }, "kind": "title", "text": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:24.257+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e4f2f96-57aa-403f-95f8-7994b8ba24a8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "Problem-Agitate-Solution", "slug": "problem-agitate-solution", "status": "active", "bestFor": "Sales pitches, urgency-driven, competitive displacement", "canonId": "019dd956-5ec6-70f9-9fd8-fdbaaff39acf", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem (Identify pain) -> Agitate (Make it worse) -> Solution (Provide relief)", "description": null, "familyLabel": null }, "from": 14, "name": "Key Takeaways", "beatId": "3200b2c0-e740-44b5-8fc8-5bd350f76fb3", "matchId": "faada6f2-2be6-4d06-8a63-ba8ef91e9a6e", "beatType": null, "evidence": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions (slide 14).", "position": 5, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 15, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 2, "textChars": 370, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:16:23.779+00", "seconds": 2.075, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-1527-7308-955d-4c9eab2bbacb/15", "deck": "/decks/019de074-1527-7308-955d-4c9eab2bbacb", "deckAnchor": "/decks/019de074-1527-7308-955d-4c9eab2bbacb#slide-15", "deckJson": "/decks/019de074-1527-7308-955d-4c9eab2bbacb.json" }, "components": [ { "bbox": { "h": 0.208, "w": 0.835, "x": 0.113, "y": 0.218 }, "kind": "list", "text": "We thank the patients who participated in this study and their caregivers, the physicians and nurses who care for them, the staff at study sites, and the staff involved in data collection and analyses\nThis study was funded by argenx\nMedical writing support was provided by Danielle Colas-Zelin, PhD, of Eloquent Scientific Solutions, and funded by argenx", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "676d63bf-6207-43a1-bf85-c94cbdc61f83", "parentComponentId": null }, { "bbox": { "h": 0.054, "w": 0.336, "x": 0.098, "y": 0.078 }, "kind": "title", "text": "Acknowledgements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:16:23.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c220d213-ad63-428d-b553-3bcbf69d818e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 2, "to": 2, "label": "Problem Identification", "description": "The document starts with a problem statement (slide 2)." }, { "from": 6, "to": 6, "label": "Agitation", "description": "Baseline characteristics show multiple prior therapies and long-standing ITP (slide 6)." }, { "from": 7, "to": 7, "label": "Solution", "description": "Efficacy endpoints were met (slide 7)." }, { "from": 8, "to": 8, "label": "Before-After Comparison", "description": "Efgartigimod demonstrated early sustained increases in platelet counts (slide 8)." }, { "from": 9, "to": 9, "label": "Comparative Analysis", "description": "Efgartigimod resulted in higher responses than placebo (slide 9)." }, { "from": 14, "to": 14, "label": "Key Takeaways", "description": "Efgartigimod Phase 3 (ADVANCE) IV Study Conclusions (slide 14)." } ], "loops": [ { "from": 11, "to": 11, "label": "Mece Breakdown", "description": "Show subgroup analysis favoring efgartigimod" } ] }